FCM
RPRX icon

Frontier Capital Management’s Royalty Pharma RPRX Stock Holding History

Frontier Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$387K Hold
8,070
– – ﹤0.01% 278
2025
Q4 		$312K Buy
+8,070
New +$308K ﹤0.01% 285

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frontier Capital Management's RPRX Position: Q1 2026 in Review

Frontier Capital Management held its Royalty Pharma (RPRX) position steady in Q1 2026 at 8,070 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #278.

Frontier Capital Management first reported a position in RPRX in Q4 2025 and has held it in 2 quarters since. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Frontier Capital Management held 8,070 shares of Royalty Pharma worth $387K as of Q1 2026.
  • Frontier Capital Management left its Royalty Pharma share count unchanged in Q1 2026.
  • Royalty Pharma made up ﹤0.01% of Frontier Capital Management's portfolio in Q1 2026, its #278 holding.
  • Frontier Capital Management first reported a position in Royalty Pharma in Q4 2025 and has held it in 2 quarters since.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Frontier Capital Management's 13F filing for Q1 2026, filed 15 May 2026.